HELSINKI, Finland – August, 2024
MVision AI is excited to announce that our application for MVision AI Segmentation (Contour+) has been approved by the Central Drugs Standard Control Organization (CDSCO) under the “Image Segmentation Application Software” category. This approval facilitates the deployment of our advanced image analysis algorithms in radiation therapy treatment planning workflows across India.
Contour+ accelerates the contouring process, promotes standardization, enhances consistency, and saves time, as confirmed by independent evaluations and customer experiences. Designed to steer clinical contouring practices towards consensus and compliance with guidelines, Contour+ represents a significant advancement in radiation therapy.
Cancer is a leading health concern in India. It is estimated that every ninth person in the country will develop cancer at some point in their life. In 2020, India reported an estimated 1.39 million cancer cases, which rose to 1.46 million in 2022. Studies estimate a 12.8% increase in annual cancer cases by 2025, reaching approximately 1.57 million.
MVision AI enhances the efficiency and ensures patients receive timely and personalized care. The integration of advanced AI solutions like Contour+ in radiation therapy departments is crucial for improving cancer treatment outcomes.
MVision AI’s comprehensive GBS™ solution enhances the expertise of Radiation Oncology professionals in AI contouring and includes a robust Return On Investment (ROI) strategy. The solution comprises three innovative products – Contour+, Guide, and Verify.
“MVision AI is thrilled to introduce our GBS solution to India. This will significantly reduce contouring time in oncology departments, ensuring standardized and efficient patient care. Our training and validation tools will keep clinical teams updated on best practices. Being selected as the preferred vendor marks an important milestone for MVision as we expand beyond Europe and the US,” says Dharani Rangaraj, CEO of MVision AI. “The CDSCO approval in India underscores the effectiveness and potential of our technology. We are dedicated to providing the best possible care to cancer patients worldwide by making our solutions accessible to all radiation oncology professionals.”
For more information on Contour+ and our comprehensive GBS™ solution, please visit MVision.ai or contact us at info@mvision.ai.
About MVision AI
MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower Radiation Oncology professionals with cutting-edge technology to streamline workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.
Contact Information
Media Contact: Sakthy Edamaruku
Email: sakthy.edamaruku@mvision.ai
MVision AI Headquarters:
Paciuksenkatu 29, 00270,
Helsinki, Finland
